Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Gene silencing and gene editing: Page 5
Bio-Rad launches new SARS-CoV-2 panels
By
LabPulse.com staff writers
Bio-Rad's Bio-Plex Pro Human IgA SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel and the Bio-Plex Pro Human IgM SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel join Bio-Rad's existing Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel to complete the set of three separate qualitative multiplex I immunoassays that detect IgA, IgM, and IgG antibodies against four SARS-CoV-2 antigens, the company said.
September 29, 2021
Bio-Techne launches multiplex spatial genomics assay
By
Samantha Black, PhD
The RNAscope HiPlex V2 assay is designed to enable a deeper understanding of gene expression patterns at a single-cell resolution. The assay can generate precision expression data from 12 targets in FFPE samples and up to 48 targets in fresh and fixed frozen samples, according to the company.
July 26, 2021
PathogenDx nabs CE-IVD Mark for DetectX-Rv test
By
LabPulse.com staff writers
DetectX-Rv will now be available for sale and distribution to qualified laboratories across the European Union. DetectX-Rv's microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV-2 within three hours after RNA extraction.
July 21, 2021
DiaSorin completes Luminex acquisition for $1.8B
By
LabPulse.com staff writers
DiaSorin first announced the acquisition in April 2021, saying that the deal would position the company as a full-fledged provider of products in both the diagnostics and life sciences segments. DiaSorin said that it sees Luminex's clinical multiplexing assays as a major asset in helping the company position itself as a provider to biopharma companies.
July 15, 2021
FDA grants EUA for PathogenDx COVID-19 test
By
LabPulse.com staff writers
DetectX-Rv is a reverse transcription polymerase chain reaction (RT-PCR) and DNA microarray test that uses material from nasopharyngeal, oropharyngeal, midturbinate, and anterior nasal swabs, as well as nasal aspirates, nasopharyngeal wash/aspirates, and bronchoalveolar lavage specimens from patients with suspected COVID-19, according to the firm.
April 26, 2021
Luminex receives $11.3M from BARDA for multiplex assay
By
LabPulse.com staff writers
The panel will be able to run on all Aries 6- and 12-cassette systems. Results will be available in less than two hours, the firm said. BARDA is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
February 18, 2021
CAP comments on Biden's COVID-19 plans
By
LabPulse.com staff writers
Major problems exist in the diagnostic testing process, whether it's obtaining testing supplies, continued access to services, or the financial effect on laboratories. CAP encourages the federal government to improve transparency, coordination, and management of testing supplies along with covering multiplex polymerase chain reaction (PCR) respiratory viral panel (RVP) tests.
January 28, 2021
Veracyte touts study on Prosigna breast cancer test
By
LabPulse.com staff writers
The study, published online October 27 in the Journal of Clinical Oncology, compared the commercial forms of four breast cancer recurrence risk tests: the Prosigna Prediction Analysis of Microarray 50 (PAM50) risk of recurrence, the Oncotype DX recurrence score, EndoPredict, and the Breast Cancer Index.
November 1, 2020
Paragon debuts more COVID-19 NGS tests
By
LabPulse.com staff writers
The tests include the CleanPlex angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) panel, a multiplex polymerase chain reaction (PCR)-based targeted sequencing assay that analyzes genetic factors impacting COVID-19 infection susceptibility and disease severity. In addition, the CleanPlex SARS-CoV-2 Flex research panel detects mutations and additional genome coverage of the novel coronavirus.
October 18, 2020
GenMark secures EUA for multiplex test
By
LabPulse.com staff writers
In less than two hours, the ePlex RP2 test can identify or rule out the responsible pathogen or pathogens to ensure proper treatment. The ePlex RP2 panel is designed for use with the firm's ePlex system, along with the ePlex RP panel and blood culture identification (BCID) panels (Gram-positive, Gram-negative, and fungal pathogens).
October 8, 2020
PathogenDx wins NIH grant to expand COVID-19 testing
By
LabPulse.com staff writers
The grant was provided under the NIH's Rapid Acceleration of Diagnostics (RADx) program for DetectX-Rv, a multiplex viral diagnostic assay that detects COVID-19, as well as COVID-like viruses and subsequent mutations from SARS-CoV-2, according to the firm. The multiplex system will enable thousands of samples to be tested each day, PathogenDx said.
July 28, 2020
Nanommune, Velox to offer microarray testing, consulting for COVID-19
By
LabPulse.com staff writers
The partnership aims to increase the adoption of high-plex microarray platforms among clinicians, laboratories, and researchers who want to use microarray technology for COVID-19 diagnostics but lack the experience and capabilities to perform high-throughput testing.
July 2, 2020
Previous Page
Page 5 of 7
Next Page